|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
ES2614274T3
(es)
*
|
2002-09-06 |
2017-05-30 |
Alexion Pharmaceuticals, Inc. |
Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
AU2004229335C1
(en)
|
2003-04-04 |
2010-06-17 |
Genentech, Inc. |
High concentration antibody and protein formulations
|
|
US7736644B2
(en)
|
2003-06-27 |
2010-06-15 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
WO2008057459A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
NZ587632A
(en)
|
2008-03-14 |
2012-06-29 |
Biocon Ltd |
An anti-cd6 monoclonal antibody and a method thereof
|
|
RU2011101969A
(ru)
|
2008-06-30 |
2012-08-10 |
Ново Нордиск А/С (DK) |
Антитела к человеческому интерлейкину-20
|
|
CA2749200A1
(en)
*
|
2009-01-29 |
2010-08-05 |
Michael Bowen |
Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
|
|
BRPI1006519A2
(pt)
*
|
2009-03-06 |
2016-08-09 |
Genentech Inc |
formulação de anticorpos
|
|
GB0904214D0
(en)
*
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
|
ES2615881T3
(es)
|
2009-05-07 |
2017-06-08 |
Stallergenes |
Uso de inmunoglobulinas igg1 y/o de ligandos del receptor cd32 para el tratamiento de enfermedades y manifestaciones inflamatorias por vía mucosa.
|
|
US8454956B2
(en)
|
2009-08-31 |
2013-06-04 |
National Cheng Kung University |
Methods for treating rheumatoid arthritis and osteoporosis with anti-IL-20 antibodies
|
|
BR112012012080B1
(pt)
*
|
2009-11-20 |
2022-11-29 |
Biocon Limited |
Formulações de histidina-trealose do anticorpo t1h
|
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
|
ES2738114T3
(es)
*
|
2010-02-11 |
2020-01-20 |
Ablynx Nv |
Métodos y composiciones para la preparación de aerosoles
|
|
EP3409289B1
(en)
*
|
2010-02-26 |
2020-09-30 |
Novo Nordisk A/S |
Stable antibody containing compositions
|
|
RU2588658C2
(ru)
|
2010-04-27 |
2016-07-10 |
ЭсСиАйЭл Текнолоджи ГмбХ |
Стабильные водные композиции белка mia/cd-rap
|
|
RU2012153786A
(ru)
*
|
2010-05-28 |
2014-07-10 |
Ново Нордиск А/С |
Стабильные многодозовые композиции, содержащие антитело и консервант
|
|
SG190006A1
(en)
|
2010-11-04 |
2013-06-28 |
Boehringer Ingelheim Int |
Anti-il-23 antibodies
|
|
EP2652498B1
(en)
|
2010-12-16 |
2018-04-18 |
F.Hoffmann-La Roche Ag |
Diagnosis and treatments relating to th2 inhibition
|
|
TWI719112B
(zh)
|
2011-03-16 |
2021-02-21 |
賽諾菲公司 |
雙重ｖ區類抗體蛋白質之用途
|
|
MX341076B
(es)
*
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
UY34105A
(es)
*
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
|
RU2640025C2
(ru)
*
|
2011-07-13 |
2017-12-25 |
Эббви Инк. |
Способы и композиции для лечения астмы с использованием антител против il-13
|
|
WO2013012022A1
(ja)
|
2011-07-19 |
2013-01-24 |
中外製薬株式会社 |
アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
|
|
AR088579A1
(es)
|
2011-10-31 |
2014-06-18 |
Genentech Inc |
Formulaciones de anticuerpos
|
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
|
CN104507497B
(zh)
*
|
2012-05-03 |
2018-10-19 |
勃林格殷格翰国际有限公司 |
抗IL-23p19抗体
|
|
MX2014014717A
(es)
*
|
2012-06-21 |
2015-03-06 |
Ucb Pharma Sa |
Formulacion farmaceutica.
|
|
US9221904B2
(en)
|
2012-07-19 |
2015-12-29 |
National Cheng Kung University |
Treatment of osteoarthritis using IL-20 antagonists
|
|
US8852588B2
(en)
|
2012-08-07 |
2014-10-07 |
National Cheng Kung University |
Treating allergic airway disorders using anti-IL-20 receptor antibodies
|
|
US8603470B1
(en)
|
2012-08-07 |
2013-12-10 |
National Cheng Kung University |
Use of IL-20 antagonists for treating liver diseases
|
|
UA117466C2
(uk)
|
2012-12-13 |
2018-08-10 |
Мерк Шарп Енд Доме Корп. |
СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
|
|
TWI679019B
(zh)
*
|
2013-04-29 |
2019-12-11 |
法商賽諾菲公司 |
抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
|
|
KR102405247B1
(ko)
|
2013-07-23 |
2022-06-07 |
바이오콘 리미티드 |
Cd6 결합 파트너의 용도 및 이에 기초한 방법
|
|
WO2015035342A2
(en)
|
2013-09-08 |
2015-03-12 |
Oligasis Llc |
Factor viii zwitterionic polymer conjugates
|
|
RU2016107435A
(ru)
|
2013-09-13 |
2017-10-18 |
Дженентек, Инк. |
Композиции и способы обнаружения и количественного определения белка клеток-хозяев в клеточных линиях и рекомбинантные полипептидные продукты
|
|
EP3683232A1
(en)
|
2013-09-13 |
2020-07-22 |
F. Hoffmann-La Roche AG |
Methods and compositions comprising purified recombinant polypeptides
|
|
BR112016008694A2
(pt)
|
2013-10-23 |
2017-10-03 |
Genentech Inc |
Métodos de previsão da reação de pacientes com asma, de previsão da capacidade de reação de pacientes com asma, de identificação de pacientes com asma, de tratamento de pacientes portadores de asma e de tratamento de asma, uso de um kit e kit
|
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
|
US8883157B1
(en)
|
2013-12-17 |
2014-11-11 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9023359B1
(en)
|
2014-07-15 |
2015-05-05 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US9051378B1
(en)
|
2014-07-15 |
2015-06-09 |
Kymab Limited |
Targeting rare human PCSK9 variants for cholesterol treatment
|
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
|
US9045548B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9017678B1
(en)
|
2014-07-15 |
2015-04-28 |
Kymab Limited |
Method of treating rheumatoid arthritis using antibody to IL6R
|
|
US9034332B1
(en)
|
2014-07-15 |
2015-05-19 |
Kymab Limited |
Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
|
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
|
IL310015B2
(en)
|
2013-12-31 |
2026-02-01 |
Access To Advanced Health Inst |
Single vial formulation
|
|
UA117608C2
(uk)
|
2014-02-21 |
2018-08-27 |
Дженентек, Інк. |
Спосіб лікування еозинофільного захворювання у пацієнта шляхом застосування біспецифічного анти-il-13/il-17 антитіла
|
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
|
US9150660B1
(en)
|
2014-07-15 |
2015-10-06 |
Kymab Limited |
Precision Medicine by targeting human NAV1.8 variants for treatment of pain
|
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
|
WO2016014775A1
(en)
|
2014-07-24 |
2016-01-28 |
Boehringer Ingelheim International Gmbh |
Biomarkers useful in the treatment of il-23a related diseases
|
|
AR101753A1
(es)
|
2014-09-03 |
2017-01-11 |
Boehringer Ingelheim Int |
COMPUESTO DE OBJETIVO A IL-23A Y TNF-a Y USO DEL MISMO
|
|
KR20210013299A
(ko)
|
2014-10-17 |
2021-02-03 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
|
CA3093383A1
(en)
|
2014-10-24 |
2016-04-28 |
Merck Sharp & Dohme Corp. |
Co-agonists of the glucagon and glp-1 receptors
|
|
MA41115A
(fr)
|
2014-12-02 |
2017-10-10 |
Biogen Int Neuroscience Gmbh |
Procédé de traitement de la maladie d'alzheimer
|
|
AR103173A1
(es)
|
2014-12-22 |
2017-04-19 |
Novarits Ag |
Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
|
|
US20180000932A1
(en)
*
|
2014-12-31 |
2018-01-04 |
Novelmed Therapeutics, Inc. |
Formulation of aglycosylated therapeutic antibodies
|
|
SG10202103879YA
(en)
|
2015-02-04 |
2021-05-28 |
Boehringer Ingelheim Int |
Methods of treating inflammatory diseases
|
|
US9139653B1
(en)
|
2015-04-30 |
2015-09-22 |
Kymab Limited |
Anti-human OX40L antibodies and methods of treatment
|
|
AU2016233398A1
(en)
|
2015-03-16 |
2017-09-07 |
F. Hoffmann-La Roche Ag |
Methods of detecting and quantifying IL-13 and uses in diagnosing and treating Th2-associated diseases
|
|
AR104847A1
(es)
*
|
2015-06-17 |
2017-08-16 |
Lilly Co Eli |
Formulación de anticuerpo anti-cgrp
|
|
KR101808234B1
(ko)
|
2015-06-23 |
2017-12-12 |
(주)알테오젠 |
IgG Fc 도메인을 가지는 융합 단백질의 안정한 액상 제제
|
|
EP3383435A4
(en)
*
|
2015-11-30 |
2019-07-10 |
Medimmune, LLC |
OPTIMIZED RATES OF AMINO ACIDS AND SUGARS AS AMORPHOUS STABILIZING COMPOUNDS IN PHARMACEUTICAL COMPOSITIONS HAVING HIGH CONCENTRATIONS IN PROTEIN-BASED THERAPEUTICS
|
|
KR20250057128A
(ko)
|
2015-12-30 |
2025-04-28 |
코디악 사이언시스 인코포레이티드 |
항체 및 이의 접합체
|
|
KR20240052871A
(ko)
|
2016-04-27 |
2024-04-23 |
애브비 인코포레이티드 |
항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
|
|
JP7461741B2
(ja)
|
2016-06-20 |
2024-04-04 |
カイマブ・リミテッド |
抗ｐｄ－ｌ１およびｉｌ－２サイトカイン
|
|
HUE063135T2
(hu)
|
2016-09-23 |
2023-12-28 |
Hoffmann La Roche |
IL-13 antagonisták alkalmazásai atópiás dermatitis kezelésére
|
|
PL3529274T3
(pl)
|
2016-10-21 |
2024-09-09 |
Biocon Limited |
Przeciwciało monoklonalne i sposób jego stosowania w leczeniu tocznia
|
|
US11779604B2
(en)
|
2016-11-03 |
2023-10-10 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses and methods
|
|
TWI716668B
(zh)
|
2017-02-01 |
2021-01-21 |
耶魯大學 |
心臟衰竭及心腎症候群之精準治療
|
|
BR112019018022A2
(pt)
*
|
2017-03-01 |
2020-06-02 |
Medimmune Limited |
Formulações de anticorpos monoclonais
|
|
AU2018250695A1
(en)
|
2017-04-14 |
2019-11-07 |
Kodiak Sciences Inc. |
Complement factor D antagonist antibodies and conjugates thereof
|
|
WO2018200533A1
(en)
|
2017-04-28 |
2018-11-01 |
Amgen Inc. |
Excipients to reduce the viscosity of antibody formulations and formulation compositions
|
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
|
PL3639845T3
(pl)
*
|
2017-07-25 |
2023-10-23 |
Jiangsu Hengrui Medicine Co., Ltd. |
Kompozycja farmaceutyczna zawierająca kompleks białka il-15 i jej zastosowania
|
|
AU2018321335B2
(en)
*
|
2017-08-22 |
2025-08-14 |
Biogen Ma Inc. |
Pharmaceutical compositions containing anti-beta amyloid antibodies
|
|
AU2018322475A1
(en)
*
|
2017-08-22 |
2020-03-05 |
Biogen Ma Inc. |
Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies
|
|
MX2020006882A
(es)
|
2018-01-05 |
2020-09-07 |
Novo Nordisk As |
Metodos para tratar inflamacion mediada por interleucina-6 sin inmunosupresion.
|
|
KR20230142806A
(ko)
|
2018-02-09 |
2023-10-11 |
제넨테크, 인크. |
비만 세포 매개 염증성 질환에 대한 치료 및 진단 방법
|
|
US12071476B2
(en)
|
2018-03-02 |
2024-08-27 |
Kodiak Sciences Inc. |
IL-6 antibodies and fusion constructs and conjugates thereof
|
|
WO2019236435A1
(en)
*
|
2018-06-07 |
2019-12-12 |
Merck Sharp & Dohme Corp. |
Lyosphere critical reagent kit
|
|
TW202011995A
(zh)
*
|
2018-07-03 |
2020-04-01 |
比利時商葛萊伯格有限公司 |
高濃度液體抗體配製物
|
|
CN113056482A
(zh)
|
2018-10-18 |
2021-06-29 |
默沙东公司 |
抗rsv抗体的制剂及其使用方法
|
|
CN120842406A
(zh)
|
2018-10-31 |
2025-10-28 |
默沙东有限责任公司 |
抗人pd-1抗体晶体及其使用方法
|
|
WO2020092015A1
(en)
|
2018-11-02 |
2020-05-07 |
University Of Rochester |
Therapeutic mitigation of epithelial infection
|
|
KR20210089215A
(ko)
|
2018-11-07 |
2021-07-15 |
머크 샤프 앤드 돔 코포레이션 |
항-lag3 항체 및 항-pd-1 항체의 공동-제제
|
|
SG11202108627SA
(en)
|
2019-02-18 |
2021-09-29 |
Lilly Co Eli |
Therapeutic antibody formulation
|
|
CN109771398B
(zh)
*
|
2019-02-25 |
2019-09-20 |
广州南鑫药业有限公司 |
一种帕拉米韦溶液型吸入剂及其制备方法
|
|
AU2020334880A1
(en)
*
|
2019-08-16 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
High concentration anti-C5 formulations
|
|
TW202123965A
(zh)
|
2019-09-09 |
2021-07-01 |
德商百靈佳殷格翰國際股份有限公司 |
抗-il-23p19抗體調配物
|
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
|
US20230043290A1
(en)
*
|
2019-12-20 |
2023-02-09 |
Ares Trading S.A. |
Igg:tgfbetarii fusion protein composition
|
|
CN115397394A
(zh)
*
|
2020-01-31 |
2022-11-25 |
赛诺菲 |
抗体的肺部递送
|
|
CA3169827A1
(en)
*
|
2020-03-10 |
2021-09-16 |
Kunwar Shailubhai |
Compositions of il-6/il-6r antibodies and methods of use thereof
|
|
GB2595299B
(en)
|
2020-05-21 |
2022-08-03 |
Mabsolve Ltd |
Modified immunoglobulin FC regions
|
|
TWI872251B
(zh)
|
2020-05-29 |
2025-02-11 |
日商中外製藥股份有限公司 |
含有抗體製劑
|
|
EP4272756A4
(en)
*
|
2021-02-05 |
2024-12-11 |
Bio-Thera Solutions, Ltd. |
ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF
|
|
JP2024535831A
(ja)
|
2021-09-15 |
2024-10-02 |
デルミラ・インコーポレイテッド |
結節性痒疹の治療のためのｉｌ－１３阻害剤
|
|
AU2024217729A1
(en)
|
2023-02-08 |
2025-08-21 |
Immunos Therapeutics Ag |
FUSION PROTEINS OF ß2 MICROGLOBULIN, HLA HEAVY CHAIN POLYPEPTIDES, AND INHIBITOR OF CD47-SIRPA
|
|
TW202544035A
(zh)
|
2023-12-14 |
2025-11-16 |
美商德米拉股份有限公司 |
用於治療全年性過敏性鼻炎之il-13抗體
|
|
WO2025128984A1
(en)
|
2023-12-14 |
2025-06-19 |
Dermira, Inc. |
Il-13 antibodies for the treatment of chronic rhinosinusitis with nasal polyps
|
|
TW202600591A
(zh)
|
2024-03-01 |
2026-01-01 |
美商德米拉股份有限公司 |
用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
|